{"title":"Mekanisme Kerja dan Target Molekuler Interleukin-1 receptor antagonist (Anakinra) pada Aterosklerosis","authors":"M. Hamidy","doi":"10.26891/JIK.V11I2.2017.1-6","DOIUrl":null,"url":null,"abstract":"Inflammation plays an important role in the development and progression of a variety of cardiovascular conditions,most notably coronary atherosclerosis and congestive heart failure. A number of inflammatory molecules have beenimplicated in these processes, including interleukin-1 (IL-1). IL-1 receptor antagonist is an endogenous inhibitor of IL-1, which competitively binds to the IL-1 type I receptor without activating it. Anakinra is a nonglycosylated, recombinantform of human IL-1ra that, like endogenous IL-1ra, competitively inhibits IL-1 by binding the IL-1 type I receptor.","PeriodicalId":385518,"journal":{"name":"Jurnal Ilmu Kedokteran","volume":"17 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Ilmu Kedokteran","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26891/JIK.V11I2.2017.1-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mekanisme Kerja dan Target Molekuler Interleukin-1 receptor antagonist (Anakinra) pada Aterosklerosis
Inflammation plays an important role in the development and progression of a variety of cardiovascular conditions,most notably coronary atherosclerosis and congestive heart failure. A number of inflammatory molecules have beenimplicated in these processes, including interleukin-1 (IL-1). IL-1 receptor antagonist is an endogenous inhibitor of IL-1, which competitively binds to the IL-1 type I receptor without activating it. Anakinra is a nonglycosylated, recombinantform of human IL-1ra that, like endogenous IL-1ra, competitively inhibits IL-1 by binding the IL-1 type I receptor.